Biotech Values

[DewDiligence]

Copaxone logs record, blowout sales in 1Q08. So
much for the quaint notion that sales had reached a
plateau on account of Tysabri. Pricing and the the weak
dollar clearly benefited sales to some degree but, all
told, these numbers are too big for pricing and currency
to be the whole story.

http://biz.yahoo.com/bw/080430/20080430005467.html

Annualized 1Q08 Sales
(as reported by Teva):

US: $1.24B (62% of total), +20% YoY, +15% QoQ
ex-US: $924M (38% of total), +64% YoY, +39% QoQ
===
Total: $2.17B, +35% YoY, +25% QoQ